Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
CAR-T Immunotherapy Targeting CD19- ALL
2027. júl. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Multi-CAR-T Cells Targeting B Cell Lymphomas
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
2027. máj. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
2027. márc. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
2027. febr. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Study Of KITE-753 in R/R B-Cell ALL
2026. dec. 31.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
2026. dec. 7.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
2026. dec. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Persistent Coronavirus Disease 2019 (COVID-19) in Patients With Malignant Lymphoma Treated With Anti-CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases.
2026. nov. 2.· Respirology case reports· PUBMED
Vizsgálat
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
2026. nov. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
2026. nov. 1.· The Lancet. Oncology· PUBMED
Publikáció
Subcutaneous panniculitis-like T cell lymphoma in a patient with multiple sclerosis during anti-CD20 therapy: a case report.
2026. okt. 30.· Journal of neurology· PUBMED
Publikáció
Anti-CD20 mediated B cell depletion exerts a distinct influence on T cell immunity by decreasing effector memory CD4 Th17 and Th1.17 subsets in multiple sclerosis.
2026. okt. 29.· Immunobiology· PUBMED
Publikáció
Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty.
2026. okt. 22.· Frontiers in immunology· PUBMED
Vizsgálat
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
2026. okt. 20.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publikáció
Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial.
2026. okt. 17.· European journal of cancer (Oxford, England : 1990)· PUBMED
Publikáció
A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis.
2026. okt. 17.· Brain : a journal of neurology· PUBMED
Publikáció
Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial.
2026. okt. 16.· European journal of cancer (Oxford, England : 1990)· PUBMED
Vizsgálat
Prospective ctDNA Testing in Large B-Cell Lymphoma
2026. okt. 15.· NA · RECRUITING· CTGOV
Publikáció
Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study.
2026. okt. 15.· Journal of neurology· PUBMED
Publikáció
Correction: Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.
2026. okt. 15.· Rheumatology advances in practice· PUBMED
Vizsgálat
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
2026. okt. 10.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Switching Beyond Rituximab in Primary Glomerular Diseases: A Systematic Review of Within-Patient Efficacy and Safety of Non-Rituximab Anti-CD20 Antibodies.
2026. okt. 10.· Antibodies (Basel, Switzerland)· PUBMED
Publikáció
Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.
2026. okt. 9.· Neurology and therapy· PUBMED
Publikáció
T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.
2026. okt. 1.· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publikáció
Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis.
2026. okt. 1.· European journal of neurology· PUBMED
Vizsgálat
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
2026. szept. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison.
2026. szept. 30.· Multiple sclerosis and related disorders· PUBMED
Publikáció
Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis.
2026. szept. 29.· Frontiers in immunology· PUBMED
Publikáció
The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis.
2026. szept. 28.· Journal of neuroinflammation· PUBMED